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Teaser: This review outlines the advantages, stabilisation and production of drug 
nanocrystals with emphasis on wet milling. Covering their pharmaceutical 







Nanocrystals are regarded as an important nanoformulation approach exhibiting 
the advantages of increased dissolution and saturation solubility with chemical 
stability and low toxicity. Nanocrystals are produced in the form of 
nanosuspension using top-down (e.g. wet milling, high pressure homogenization) 
and bottom-up methods (e.g. antisolvent precipitation). Wet milling is a scalable 
method applicable to drugs with different physicochemical and mechanical 
properties. Nanocrystalline-based formulations, either as liquid nanosuspensions 
or after downstream processing to solid dosage forms, have been developed as 
drug delivery systems for various routes of administration (i.e. oral, parenteral, 
pulmonary, ocular and dermal). In this review, we summarize and discuss features, 
preparation methods and therapeutic applications of pharmaceutical nanocrystals 





The physicochemical properties of many new chemical entities (NCEs), which are 
developed as future drug candidates, are moving towards higher molecular weight 
and higher lipophilicity in the quest for biological selectivity and specificity [1]. 
These physicochemical properties often result in compounds with low aqueous 
solubility. Thus, many of the NCEs arising from high throughput screening and 
combinatorial chemistry methodologies (> 40%) suffer from poor solubility in 
aqueous media and some of them simultaneously in organic solvents [2]. The poor 
solubility of a compound is related with several biopharmaceutical problems. For 
example, in the case of oral administration, NCEs which possess limited solubility 
and dissolution rate in the digestive juice may display low bioavailability, high 
fed/fasted state variability, high interpatient variability, retarded onset of action, 
lack of dose proportionality and local irritation [3]. It is evident then, that the 
limitation of poor solubility which constitutes one of the main reasons for the 
discontinuation of development of NCEs, makes their formulation very 
challenging.  
 
In the past, the pharmaceutical industry considered these compounds as highly 
risky development candidates. However, nowadays mainly due to their prevalence, 
‘industry consensus has shifted from an attitude of avoidance to one of acceptance 
and increasing research dedication is given to solving solubility challenges’ [4].  
 
Several formulation strategies are currently used in order to improve the solubility, 
dissolution rate and subsequent bioavailability of drugs. These strategies include 
modifications of the drug properties on the molecular level (e.g. salt or prodrug 
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formation, use of co-solvents, complexation with cyclodextrins), the use of 
colloidal drug delivery systems (e.g. microemulsions, self-microemulsifying 
systems) or modifications of the drug properties on the particulate level (e.g. 
particle size reduction, amorphization) [5].  
 
2. Nanoparticles in drug delivery 
Nanotechnologies are considered one of the most prevalent improvement methods 
and have been used to overcome the problem of poor solubility and thus 
bioavailability, as well as to achieve targeted drug delivery. 
 
Despite the importance of nanoparticles, there is no single definition of 
nanoparticles. This may be due to the highly multidisciplinary nature of 
nanotechnology. The term nanotechnology was first used by the scientist Norio 
Taniguchi in 1974, at the University of Tokyo in Japan, for any material in the 
nanometre size range [6]. 
According to the U.S. Food and Drug Administration (FDA), materials are 
classified as being in the nanoscale range if they have at least one dimension at the 
size range of approximately 1-100 nm. However, as many properties characteristic 
of the nanoscale (e.g. solubility, light scattering, surface effects) are predictable 
and continuous characteristics of the bulk materials [7], the definitions of 
“nanomaterial” based on size are often inconsistent and the upper end of the 
nanoscale at 100 nm is an arbitrary cut-off size [8]. Thus, the 100 nm limit is often 
considered constraining and according to a more inclusive definition: particles 
below 1000 nm in each dimension (submicron particles) are designated as 
nanoparticles [9]. The latter definition is applicable in the pharmaceutical field as 
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particle size in the nanometre range can lead to increased dissolution rate due to 
the increase in surface area and increased saturation solubility [10].   
Various types of nanotherapeutics have been applied in drug delivery. The types 
of nanotherapeutics approved for oral or parenteral drug delivery in the EU market 
include liposomes, nanoemulsions, polymeric therapeutics, polymeric 
nanoparticles, virosomes, nanocomplexes and nanocrystals (Fig.1, [11])  
 
3. Nanocrystals 
Nanocrystals are nanosized drug particles. Nanocrystals are typically produced in 
the form of nanosuspensions, which are submicron (colloidal) dispersions of drug 
particles, stabilized by surfactants, polymers, or a mixture of both [12]. According 
to a stricter definition, a formulation should have a volume median diameter (D50) 
below 1μm and a volume diameter 90% undersize (D90) below 2.5 μm to be 
classified as a nanosuspension (Fig. 2, [13–15]). At this point, it should be noted 
that while dynamic light scattering is a common ensemble technique for the 
determination of the particle size of the nanosuspensions, it can lead to false 
assumptions regarding the particle size and should always be complemented with 
additional techniques like transmission electron microscopy [16,17]. The term 
nanocrystals, although implying the particles are in a crystalline state, which is 
true for most of the reported cases, has been extended to describe nanosized 
suspensions of partially crystalline [18] or even amorphous drugs formed due to 
changes from the crystalline to the amorphous form during processing [19,20]. In 
the strict sense, such an amorphous drug nanoparticle should not be called a 
nanocrystal. Recently, preparation of nanosized drug particles in the amorphous 
state is gaining momentum as the combination of size reduction with 
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amorphization has shown clear superiority for enhancing the dissolution rate and 
solubility of poorly soluble drugs. Various terms have been used for the description 
of nanoparticles in the amorphous state (e.g. ‘amorphous nanoparticles’ [21], 
‘amorphous drug nanosuspensions’ [22] and even ‘nanosuspensions’ [18]).  
 
Drug nanosuspensions have been suggested as a universal delivery approach for 
orally administered drug molecules that fall into class II (low solubility, high 
permeability) and class IV (low solubility, low permeability) of the 
Biopharmaceutics Classification system (BCS) [9,23]. Butler and Dressman [24] 
proposed the Developability Classification System (DCS) as a way to categorize 
compounds in a more bio-relevant manner.  According to the DCS, which 
distinguishes between dissolution rate-limited (DCS Class IIa) and solubility-
limited compounds (DCS Class IIb), the intrinsic solubility and the related 
intraluminal drug concentration for compounds belonging to Class IIb and IV are 
too low to achieve sufficient flux over the epithelial membrane. Hence, 
complexation or formulation approaches based on solid state modification may be 
preferable compared to nanocrystals for compounds belonging to DCS Class IIb 
and IV [25–27].  
 
Yalkowsky and co-workers established the General Solubility Equation, in which 
the solubility of a compound is expressed as a function of the melting point and its 
lipophilicity (in form of octanol-water partition coefficient, log Kow) [28]. Poorly 
soluble drugs are often referred to as "grease balls" and "brick dust" molecules. 
Specifically, "grease balls" represent highly lipophilic compounds (log Kow > 3) 
which are poorly hydrated and their solubility is solvation limited while "brick 
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dust" compounds display lower lipophilicity and higher melting point (m.p. > 200 
o C) and their solubility is limited by the strong intermolecular bonds within the 
crystal [29]. Brick dust molecules have been found to benefit from formulation 
approaches such as particle size reduction and amorphization while grease balls 
can be formulated as lipid-based formulations [30]. Thus, formulating drugs as 
nanocrystals should be mainly employed as a solubility enhancement formulation 
approach to brick dust molecules rather than to grease balls.  
 
From the different types of nanotherapeutics, specific focus will be given to 
nanocrystals in the context of this review. Nanocrystals possess a high drug 
loading (close to 100%) in contrast to matrix nanoparticles consisting of polymeric 
or lipid matrices. Thus, the main advantage of nanocrystals is the low amount of 
excipients used allowing high drug concentration at the site of action and reduction 





4. Advantages of nanocrystals in drug delivery 
The increased saturation solubility and dissolution rate are the most important 
features of nanosuspensions. Regarding the saturation solubility, which for drug 
particles in the micrometre size range and above is a constant depending on 
temperature and dissolution medium, in the case of submicron particles, it depends 
on their size and is reported as ‘apparent’ saturation solubility [31]. The enhanced 
‘apparent’ saturation solubility of nanosuspensions has been attributed to the 
increased curvature of nanoparticles resulting in increased dissolution pressure and 












 . . . Equation 1 
 
where S is the drug solubility at temperature T, S0 is the solubility of infinite big 
particle material, R is the gas constant, Vm is the molar volume, T is the 
temperature, r is the particle diameter, γ is the surface free energy, M and ρ are the 
molecular weight and density of the compound, respectively.  
 
The reduced particle size and high surface area per unit mass of the nanoparticles 















 is the dissolution rate of non-formulated drug particles, D is the diffusion 
coefficient, S is the surface area of drug particles, h is the thickness of the diffusion 
layer, Cs is the saturation solubility of the drug particles and m is the concentration 
of the drug in solution. Therefore, by reducing the particle size, the total surface 
area, S, will increase resulting in a more rapid dissolution, particularly under sink 
conditions (C << Cs).  
 
Moreover, according to the Prandtl equation (Eq. 3), the diffusion distance, h, is 
decreased for very small particles.  
 
hH = 𝑘 (
𝐿1 2⁄
𝑉1 3⁄
) .  .  .  Equation 3 
 
where hH is the hydrodynamic boundary layer thickness, k is a constant, V is the 
relative velocity of the flowing liquid against a flat surface and L is the length of 
the surface in the direction of the flow. Thus, apart from the surface effect, the 
simultaneous increase in the saturation solubility, Cs, and decrease in the diffusion 
distance, h, lead to an increase in the concentration gradient, (Cs-C)/h, thus 
increasing the dissolution rate according to the Nernst and Brunner equation (Eq. 
2, [10]).   
 
Due to the increased dissolution rate and enhanced saturation solubility, 
nanocrystals result in improved bioavailability [23,32]. Specifically, regarding 
oral drug delivery, nanocrystals have been used to address the issue of low 
bioavailability with reduced food effect compared to micronized drug [33].  
Focusing on the influence of nanonization on the dissolution rate and saturation 
10 
 
solubility, the increase in dissolution rate remains the main effect of nanosizing 
while it is not clear to what extent the saturation solubility can be increased solely 
as function of smaller particle size [25]. Van Eerdenbrugh et al. [34] determined 
the solubility of crystalline drug nanosuspensions using various methods (e.g. 
separation-based methods, light scattering, turbidity). Based on the results of their 
study, solubility increases of only 15% were measured, highlighting that solubility 
increases due to nanosization are relatively small. These measurements are in 
agreement with what would be predicted based on the Ostwald-Freundlich 
equation (Equation 1). Solid state changes induced by particle breakage and 
increased surface wettability due to the presence of the stabilizer may also lead to 
enhancement of the ‘apparent’ saturation solubility and dissolution rate of 
nanosuspensions compared to micronized suspensions. Therefore, it is evident that 
the formulation and processing of drug nanocrystals are very important for their 
in-vitro and in-vivo performance. 
 
Nanocrystals also enhance adhesiveness to the gastrointestinal mucosa, resulting 
in prolonged gastrointestinal residence and thus increased uptake via the 
gastrointestinal tract [35]. Jain et al. [36] incorporated nanosuspensions of 
ciprofloxacin into hydrogels; the formulations exhibited increased gastric 
residence time and satisfactory physical stability indicating their potential for the 
treatment of typhoid fever.  
 
Formulating a drug as a nanosuspension has also been proposed as a method to 
mitigate challenges related to the chemical stability of solution formulations. For 
example, nanosuspensions of quercetin, a nutraceutical compound, appeared to be 
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photostable with no significant content loss over one month. In contrast, for the 
solution, a 28.3% reduction in drug content and discoloration were observed over 
the same period [37].  
Apart from their superior clinical performance, nanosuspensions have attracted the 
interest of drug formulators as they can extend the life cycle of an active 
pharmaceutical ingredient (API) after patent expiration [23]. Moreover, 
nanosuspensions can be used as formulations during the whole drug development 
spectrum. Their quantitative and easy oral administration allows them to be used 
for preclinical animal studies [38], while due to the scalability of their production 
(e.g. wet milling), formulation amounts ranging from few mL up to a few liters 
can be generated. Small amounts are useful during preformulation stages while 
larger quantities are required during toxicological and pharmacokinetic studies in 
animals and for clinical trials under good manufacturing practices. All these 
characteristics have resulted in the rapid commercialization of nanosuspensions.  
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5. Stabilization of nanosuspensions 
 
Nanosuspensions are thermodynamically unstable systems due to their large 
interfacial area, and thus they possess high interfacial free energy. The surface free 
energy (ΔG) termed ‘Gibb’s energy’ associated with this area is given by Eq. 4: 
 
𝛥𝐺 = 𝛾𝑆𝐿 ∗ 𝛥𝛢 − 𝑇 ∗ 𝛥𝑆 . . . Equation 4 
where ΔA is the change in surface area, γSL is interfacial tension between the solid 
and liquid interface, T is the absolute temperature and ΔS is the change in entropy 
of the system. Therefore, the particles of a nanosuspension tend to aggregate in 
order to minimize the surface energy of the system.  
For a nanosuspension to be stable it must contain a third component known as 
stabilizer additional to the solid particles and liquid, such as a surfactant and/or 
polymer. Kinetically, the process of aggregation depends on its activation energy. 
Addition of stabilizers suppresses aggregation by increasing the activation energy 
of the process [39]. 
The mechanisms of stabilization provided by the stabilizers can be classified as 
electrostatic repulsion and steric stabilization. Both mechanisms of stabilization 
can be achieved by incorporating ionic and non-ionic stabilizers into the 
nanosuspension medium. Stabilization by electrostatic repulsion can be explained 
by the DLVO theory [40].  
 
Steric stabilization is mainly achieved by amphiphilic non-ionic stabilizers and can 
be described by the solvation effect. The non-ionic macromolecules orientate 
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themselves at the solid-liquid interface where they are adsorbed onto the particle 
surface through an anchor segment, while the well-solvated tail segment protrudes 
into the bulk medium. As two particles approach each other, the well-solvated 
segments of the stabilizer may interpenetrate. If the medium is a good solvent for 
the stabilizer molecules, the adsorbed segments on the particles cannot 
interpenetrate as the resultant desolvation is thermodynamically disfavoured [41]. 
Compared to electrostatic repulsion, steric stabilization is comparatively non-
dependent on the presence of electrolytes in the medium and it is equally effective 
for both aqueous and non-aqueous dispersion media. Considering the changes of 
the pH along the gastrointestinal tract, steric stabilization exhibits advantages over 
electrostatic repulsion as a mechanism of stabilization.  
 
Combination of the mechanisms of stabilization is often referred to as electrosteric 
stabilization. Electrosteric stabilization can be achieved by stabilizers which 
contain both a polymeric chain and charged groups (e.g. multi-amine containing 
polyelectrolytes, [42]) or by combining a non-ionic polymer and an ionic 
surfactant. Electrosteric stabilization has been suggested as a synergistic 
stabilization strategy due to the electrostatic repulsion between particles and 
enhanced steric hindrance from the adsorbed polymers [43].  
 
Various types of generally recognised as safe (GRAS) pharmaceutical excipients 
have been used as stabilizers of drug nanosuspensions. Detailed reviews and tables 
on the use of polymers and surfactants as stabilizers of drug nanosuspensions are 
provided by Peltonen et al. [44] and Tuomela et al. [30]. 
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The type and concentration of stabilizer used have been found to strongly influence 
the particle size and the size reduction kinetics of the nanosuspension produced 
[39,45]. Ito et al. [46] studied the effect of polymer species and concentration on 
the production of mefenamic acid nanosuspensions and they reported that there is 
a relationship between polymer affinity, solubilisation capacity and final particle 
size achieved. More specifically, they reported that there is an optimum stabilizer 
concentration for forming stable nanosuspensions with small particle size. When 
the stabilizer is present in the system in concentrations far above or below the 
optimum concentration, the nanosuspensions are prone to instability phenomena 
due to particle growth (Fig. 3). In the case of insufficient amount of stabilizer, the 
surface of the nanocrystals is not completely covered by the stabilizers and thus 
particle growth can be manifested due to particle aggregation. In the case of 
stabilizer overdosing, particle growth can be the result of Ostwald ripening in 
which larger particles grow at the expense of the smaller particles due to 
differences in solubility, as a function of the particle size [47].   
Currently, the selection of a suitable stabilizer for a drug nanosuspension is based 
on trial and error. Few studies attempt to develop a rational approach for the 
selection of the appropriate stabilizer based on the physicochemical characteristics 
of the API in question. In this direction, George and Ghosh [48] studied the wet 
milling of six APIs with four different stabilizers to identify the material property 
variables (API and stabilizer) that control the critical quality parameters, which 
play a role in nanosuspension stability. They identified, the log P, the melting point 
and the enthalpy of fusion as the key drug properties that have a direct effect on 
nanosuspension stability. They highlighted that the most likely candidate for wet 
milling is a drug with a high enthalpy of fusion and hydrophobicity which can be 
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stabilized either electrostatically or sterically. At this point, it should be noted that 
other studies which investigated the stabilization of various drugs using different 
stabilizers at various concentrations have reported no correlation between the 
physicochemical characteristics of a drug (e.g. molecular weight, melting point, 





6. Formation of nanocrystals 
 
Methods for the production of nanosuspensions can be categorised as top-down 
and bottom-up methods, depending on the starting material. In top-down methods, 
such as wet milling, high-pressure homogenization and microfluidisation, the 
starting material comprises larger solid particles than the resulting nanoparticles 
and mechanical processes are the fundamental mechanism causing particle size 
reduction. In bottom-up methods, particles are formed from the molecular level. 
Such methods are further subdivided into solvent evaporation (e.g. spray drying, 
electrospraying, cryogenic solvent evaporation, etc.) and antisolvent methods (e.g. 
liquid antisolvent, supercritical antisolvent, etc.) [51]. 
 
The main advantage of top-down over bottom-up methods is the production of 
nanosuspensions with high drug loading. Moreover, they do not involve harsh 
organic solvents since the solvent in which drug is dispersed, but not dissolved, is 
water for most poorly water-soluble drugs, making the top-down methods eco-
friendly. This permits the formulation of many poorly soluble APIs, characterized 
as ‘brick dust’, suffering from poor solubility in a wide range of solvents. In 
general, because of the more streamlined process-flow and the solvent-free feature 
of top-down methods, most of the marketed and developmental nanosuspension-
based pharmaceutical formulations have been produced by top-down methods. 
 
From the various methods for the production of nanocrystals, the method of wet 
milling is considered in depth in the following section of this review, as it is the 
production method behind the majority of the marketed and developmental 
nanosuspension-based pharmaceutical formulations (Table 1).  
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7. Milling  
Milling is a common physical unit operation for particle size reduction frequently 
applied in pharmaceutical formulation. During milling, mechanical energy imparts 
stress to particles which are strained and deformed. Fracture takes place through 
crack formation and crack propagation. For crystalline materials, fracture occurs 
preferentially along their crystal cleavage planes and increased concentration of 
crystal lattice imperfections makes fracture easier compared to crystals with fewer 
internal weaknesses. According to Heinicke [52], the main stress types applied in 
mills are compression, shear and impact, the latter can be further divided to stroke 
and collision. Wet milling will be discussed and its application in drug 
nanonization will be considered in more detail.  
 
7.1. Wet milling  
Milling a solid suspended in a liquid is referred to as wet milling. Experimental 
data on the wet milling of various materials suggest that the breakage rate kinetics 
(i.e. the median particle size versus milling time) follow a first-order exponential 
decay with longer milling times result in finer suspensions. The initial fast breakage 
of crystals can be attributed to the existence of more cracks and crystal defects in 
the larger crystals which propagate breakage relatively easy. After the initial fast 
breakage stage, size reduction continues but at a remarkably slower rate until a 
plateau is reached. The reduced rate of particle size reduction and finally the 
achievement of a plateau (steady state) suggest that in the later stages of wet milling 
the mechanism of fracture changes. As the particle size decreases with increasing 
milling time, the shear stress of the suspension increases and thus attrition becomes 
the dominant mechanism of comminution [53].  
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Understanding of the breakage kinetics for a specific drug and milling set up is 
important for determining the milling duration that should be selected in order to 
achieve particles of the desired fineness. Various mathematical modelling 
approaches have been developed to describe the impact of process parameters (e.g. 
milling speed, bead concentration, drug loading, etc.)  on the breakage kinetics and 
particle size distribution. These modelling approaches extend from purely 
descriptive dynamic models to discrete element modelling, population balance 
models and microhydrodynamic models. A detailed review on the models that have 
been developed for enhanced understanding of milling processes is provided by 
Bilgili et al. [54].  
Regarding pharmaceutical manufacturing, the two most common types of wet mills 
used are: the rotor-stator and the media mills.  
7.2. Rotor-stator mixers/wet mills  
Rotor-stator mixers consist of a high-speed mixing element (the rotor) in close 
proximity with a static element (the stator). They are also referred to as high-shear 
devices as the shear rates generated in these devices are orders of magnitude higher 
than in a conventional mechanically stirred vessel. Rotor-stator mixers are mainly 
used for homogenization and emulsification purposes. However, the common 
action of the rotor and the stator results in shear stress, turbulence and cavitation 
forces which apart from mixing lead to size reduction [55].   
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7.3. Wet media mills 
The second type of mills used for wet milling are media mills. Wet media milling 
involves feeding the milling chamber with the milling media (e.g. milling beads), 
the particulate material, the stabilizer and a suitable solvent or mixture of solvents. 
The milling beads are made of a hard and dense material such as yttrium-stabilized 
zirconium oxide, stainless steel, glass alumina, titanium or certain polymers as 
highly cross-linked polystyrene and methacrylate. The beads size may vary from 
less than 0.1 mm to 20 mm. As a rule of thumb, the smaller the size of the milling 
beads the finer the nanoparticles produced, due to increased collision frequency 
between drug particles and beads. However, too small beads (e.g. 0.03 mm) may 
not be suitable for milling as they cannot generate sufficient energy for particle 
breakage when they impact with drug particles due to their light weight.  
7.3.1. Wet media milling equipment 
Wet media milling equipment that used for the production of nanosuspension can 
be divided into planetary ball mills and wet stirred media mills. Planetary ball mills 
are high-energy ball mills and their name is derived from the kinematics of the 
grinding components which are analogous to the rotation of the earth around the 
sun. A planetary mill is usually made of two or more jars, rotating at an angular 
velocity (ω) around their axis, installed on a disk rotating at an angular velocity (Ω, 
Fig. 4). Usually for colloidal milling, the ratio between the speed of the rotating 
disk and the milling jar is 1: -2, this means that during one rotation of the disk the 
jar rotates twice in the opposite direction. Comminution occurs by impact, 
frictional and shear forces resulting from collision among the particles, the milling 
media and the wall of the milling jars. Coriolis and centrifugal forces lead to a rapid 
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acceleration of the milling media which results in the production of particles in the 
submicron range [56]. 
Apart from some newly launched models (e.g. Emax, Retsch), the majority of 
planetary ball mills do not have any integrated cooling system. This means that a 
major part of the energy introduced into the milling chamber is transformed into 
heat and dissipated into the suspension. The increase of temperature during milling 
is considered as an additional mechanism behind the reduction of particle size. 
Steiner et al. [57] prepared nanosuspensions of lactose in ethanol and reported a 
strong influence of the suspension temperature on the resulting particle fineness.  
Planetary ball mills are mainly used for the development of drug nanosuspensions 
at the laboratory scale due to their mechanical simplicity and versatility. Wet 
milling using planetary ball mills has been successfully employed to produce 
nanosuspensions for drugs such as indometacin and brinzolamide [45,58]. Based 
on the principle of planetary ball milling, Juhnke et al. [59] developed a screening 
media milling equipped with up to 24 milling beakers of 0.05-1.0 mL individual 
milling chamber volume. Scaling-up studies to a laboratory stirred media mill 
resulted in satisfactory comparability, indicating that a particle formulation 
optimised in a planetary ball mill can be transferred to other mill types which are 
used for the production of larger batch size. Therefore, the screening media mill is 
a useful tool for the accelerated preclinical and clinical pharmaceutical 
development of formulations based on nanomilling.  
Wet stirred media mills are the most commonly used type of mills to produce drug 
nanosuspensions. In stirred media mills, milling media are moved by a rotating 
agitator and production of submicron particles can be achieved due to a very high 
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number of stress events per unit time and unit volume and due to an appropriate 
stress intensity [60]. The mills used to produce nanosuspensions are high-speed, 
closed-type stirred media mills, operating at circumferential stirrer speed of 8 to 20 
m s-1. They are equipped with a separation device (screen or rotating gap) which 
allows the free discharge of the product but prevents the milling media from leaving 
the chamber. Mill designs vary in the chamber volume capacity (ranging from less 
than 1 L to more than 1 m3) and the stirrer geometry (e.g. disk, pin-counter-pin 
stirrer). Usually, this type of mills is equipped with a cooling system allowing 
precise temperature control but also processing of thermolabile compounds as 
product overheating can be prevented. Detailed studies on the impact of process 
parameters on the breakage kinetics of poorly water-soluble drugs have been 
provided by Afolabi et al. [61] and Li et al. [62]. 
Wet stirred media mills can operate in batch, recirculation or continuous mode. 
Batch mode is mainly restricted in the development of nanosuspensions at the 
laboratory scale. In recirculation mode, a recirculation pump and a holding tank 
are added in the milling set-up (Fig. 5). The pump is employed to circulate the 
suspension from the holding tank, through the mill, and back into the holding tank, 
allowing the production of a fixed batch size as determined by the capacity of the 
holding tank [63]. In continuous operation, a receiving tank is also used allowing 
the continuous withdrawal of product from the mill. There are two types of 
continuous mode: the multi-pass continuous and the cascade-continuous mode. In 
multi-pass continuous mode, the suspension flows from the holding tank, through 
the mill and into the receiving tank while in the cascade-continuous mode, the 
suspension flows from the holding tank, through mills in series and into the 
receiving tank [63]. The fact that wet stirred media milling can be employed in a 
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continuous mode is a significant advantage of the process as nowadays the 
pharmaceutical manufacturing sector is moving towards the implementation of 





8. Applications of nanocrystals in drug delivery 
8.1. Oral drug delivery 
 
Oral drug delivery is the most popular and convenient route of administration for 
nanocrystalline-based products. As presented in Table 1, these products have been 
developed either as liquid oral dosage forms (i.e. suspensions) or as solid oral 
dosage forms (i.e. tablets and capsules). Regarding the solid oral dosage forms, a 
solidification step is employed after the preparation of nanosuspensions. Spray and 
freeze drying (lyophilization) are the most commonly used techniques while 
fluidised-bed coating, granulation and pelletisation yield formulations with more 
straightforward downstream processing to tablets or capsules. Other techniques 
such as spray-freeze drying, aerosol flow reactor and printing, which are less 
frequently applied in pharmaceutical technology have also been employed [64]. It 
is important for the solid nanocrystalline-based formulations to retain their 
redispersibility (i.e. ability to reform nanoparticles upon rehydration) as it is a 
prerequisite for their superior clinical performance. For this purpose, addition of 
matrix formers (e.g. sugars) is a common strategy in order to produce redispersible 
solid nanocrystalline formulations [65]. 
 
Rapamune® (Wyeth) is a nanocrystalline-based formulation of the macrocyclic 
immunosuppressive drug sirolimus (rapamycin). It was the first nanocrystalline 
product to reach the market and is available in two formulations: oral suspension 
and tablets [10]. The product was developed using Elan’s NanoCrystal® 
technology in order to eliminate limitations related to the first commercially 
available formulation of sirolimus, which is a viscous oral solution of the drug in 
Phosal 50 PG and polysorbate 80. The lipid-based liquid solution needs to be 
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refrigerated and protected from light upon storage, it is unpalatable and its 
dispensing protocol is complicated [66]. Rapamune® tablets, on the other hand, 
exhibited a 27% increase in the bioavailability of the drug compared to the lipid-
based solution and their ease of administration contributes to enhanced patient 
adherence to medication [67].  
 
Emend® (Merck) is a nanocrystalline-based product of the antiemetic drug 
aprepitant which was developed using Elan’s NanoCrystal® technology. It is 
formulated as capsules containing sugar beads coated with an aprepitant 
nanosuspension. Nanonisation of aprepitant eliminated the high fasted/fed state 
variation related to the conventional micronized formulation used in early clinical 
studies [33]. A similar concept can be found behind the development of Megace 
ES® (Par Pharmaceutical) which is a ready-to-use liquid nanosuspension of 
megestrol acetate. Megace ES® is indicated as an appetite stimulant for the 
treatment of anorexia and weight loss in patients with HIV. While the oral solution 
of megestrol acetate exhibited significant food effect, Megace ES® managed to 
increase the bioavailability of the drug and reduce the food effect, thus allowing 
the administration of the drug in the fasted state. Considering that the patient 
population for this drug exhibits difficulties in consuming food, Megace ES® as a 
stable and non-viscous nanosuspension contributed to enhanced patient adherence 
to medication [67]. 
Tricor® (Abbott) is a nanocrystalline-based formulation of fenofibrate for the 
treatment of hypercholesterolemia. The product is based on Elan's NanoCrystal® 
technology and it is available in the form of tablets. Launching Tricor® as a 
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nanocrystalline formulation was part of the company's strategy involving the 
sequential launch of branded reformulations of fenofibrate in order to maintain a 





8.2. Parenteral drug delivery 
 
Via the parenteral route of administration (i.e. subcutaneous, intramuscular, 
intravenous, intradermal and intra-arterial injection) the drug can be administered 
directly into a blood vessel, organ, tissue or lesion. Nanotherapeutics hold great 
potential for selective and controlled delivery of drugs to target cells and organs 
[69,70]. Two additional advantages of nanocrystals regarding parenteral drug 
delivery are the high drug loading and the ease of sterilisation of these formulations 
using conventional methods including gamma irradiation, filtration and thermal 
sterilisation [71]. Currently, several poorly water-soluble drugs have been 
formulated as nanocrystals for intravenous, intramuscular and intraperitoneal 
administration [72]. At this point, it should be highlighted that for nanosuspensions 
intended to be administered intravenously, the particle size stability of 
nanocrystals upon storage is of paramount importance and the content of particles 
larger than 5 μm should be controlled strictly to avoid capillary blockade and 
embolism.  
Regarding intravenous (IV) administration, a few studies have reported the 
development of nanocrystals as tumour-targeting drug delivery approach. The 
main impetus to formulate drugs as nanocrystals for IV administration has been 
the enhanced permeation and retention effect that facilitates passive accumulation 
of particles (20-300 nm) in tumour tissues. Shegokar et al. [73] prepared 
nanosuspensions of the antiretroviral drug nevirapine (457 ± 10 nm) for HIV/AIDS 
chemotherapy. The nanosuspensions were further surface-modified by stabilizer 
adsorption, e.g. serum albumin, polysaccharide and PEG 1000. The non-modified 
and surface-modified nanosuspensions were tested for their targeting potential to 
the mononuclear phagocytic system cells by in-vitro protein adsorption studies 
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using two-dimensional polyacrylamide gel electrophoresis. In the adsorption 
patterns of both non-modified and surface-modified nanosuspensions, high 
amounts of immunoglobulins were determined indicating uptake by the liver and 
spleen.  In a follow-up study, the biodistribution, uptake and toxicity profiles of 
the nanosuspensions (non-modified and surface-modified) were tested after IV 
administration to rats and compared to the plain drug solution. Surface-modified 
nanosuspensions exhibited improved drug accumulation in various organs of the 
rat such as the brain, liver and spleen, suggesting that nanonisation of nevirapine 
significantly improved its in-vivo behaviour and thus is a promising formulation 
approach for targeting antiretroviral drugs for HIV/AIDS to cellular reservoirs 
[73].  
InvegaSustenna® (Johnson & Johnson) is an extended-release nanosuspension of 
the antipsychotic drug paliperidone palmitate which has been found effective in 
controlling the acute symptoms of schizophrenia and delaying relapse of the 
disease. The formulation, as a nanosuspension, was developed using Elan’s 
NanoCrystal® technology. The product is available in ready-to-use prefilled 
syringes and is administered once-monthly by intramuscular injection following a 
specific protocol which consists of an initial dosing and a maintenance dosing 
period. The concept behind the development of Invega Sustenna® is different 
compared to the other nanocrystalline-based products. In other words, 
paliperidone (parent drug) does not exhibit any solubility issues and its conversion 
to paliperidone palmitate (prodrug) in combination with its nanonization is an 
approach for limiting its solubility and thus sustaining drug release [67]. That 
InvegaSustenna® is administered once-monthly is a great advantage giving 
increased product safety, tolerability and most importantly improved patient 
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adherence to medication compared to other antipsychotic drugs that require daily 
dosing.   
 
8.3. Pulmonary drug delivery 
Many of the advantages outlined in section 4 can be extended to pulmonary drug 
delivery. Regarding drug delivery to the lungs, drug absorption and local 
bioavailability depend upon the fraction of the drug which is deposited and 
dissolved in the lung fluids. Once the particle has deposited on the lung surface, 
mucociliary clearance and drug absorption are two competitive mechanisms 
influencing the fate of the drug. Specifically, when mucociliary clearance takes 
place faster than drug absorption, as in the case of drugs with low dissolution rate, 
this can lead to reduction in the bioavailability. Formulations consisting of 
nanoparticles have been found to promote more rapid absorption following 
inhalation of poorly water-soluble drugs which suffer from dissolution-limited 
absorption (e.g. beclometasone dipropionate, budesonide, itraconazole, [74]). 
Nanosuspensions have been proposed as a formulation approach to increase the 
dissolution rate and thus the absorption of poorly water-soluble inhaled 
corticosteroids such as fluticasone propionate and budesonide which constitute 
indispensable drugs in the armamentarium against asthma and other respiratory 
diseases [75]. Britland et al. [76] compared the bioavailability, emission 
characteristics and efficacy of a budesonide nanosuspension with those of a 
micronized suspension of the drug after delivery as a nebulised aerosol to a human 
airway epithelial culture cell line. For an equivalent dose, the budesonide 





Apart from the use of nanosuspensions in nebulisers, solidification of 
nanosuspensions to respirable nanoparticle agglomerates (aerodynamic diameter 
between 1-5 μm) has been applied to prepare dry powders for inhalation [77,78]. 
According to El-Gendy et al. [79,80], the controlled agglomeration of 
nanosuspensions to inhalable nanoparticle agglomerates is “an approach to 
harmonise the advantages of nanoparticles with the aerodynamics of small 
microparticles so as to achieve an improved bioavailability and aerosolization 
behaviour of the drug”. Production of nanosuspension by wet media milling and 
subsequent solidification by spray drying after the addition of GRAS excipients, 
such as mannitol (matrix former) and L-leucine (aerosolization enhancer), has 
been applied as a platform for the formation of respirable nanoparticle 
agglomerates. The nanoparticle agglomerates produced by this platform were 
found to exhibit enhanced aerosolization and dissolution performance while they 
retained their crystallinity, which is beneficial for their long-term stability upon 
storage [81]. By careful selection of the formulation and process parameters, which 
can be facilitated using design of experiments methodology, this platform can be 
successfully applied to various drugs with different physicochemical properties 





8.4. Ocular drug delivery 
Ocular drug delivery is the preferred route of administration for pathologies of the 
eye such as infections, inflammation, dry eye syndrome, glaucoma and 
retinopathies. The complex structure and nature of the eye poses challenges to 
formulation scientists due to the very low ocular drug bioavailabilty (usually less 
than 5%). Research has focused on nanocarrier-based drug delivery systems (e.g. 
liposomes, polymeric micelles) as they are capable of overcoming many of the 
biological barriers of the eye and thus enhancing ocular drug bioavailability. 
Recently, the use of nanocrystals as an ocular formulation approach for poorly 
water-soluble drugs is gaining popularity and this can be attributed to the faster 
clinical development and commercialisation of nanocrystals compared to other 
types of nanotherapeutics such as liposomes and dendrimers [83]. According to 
Sharma et al. [84], the advantages of nanocrystals for drug delivery to the eye are: 
improved ocular safety, increased retention of the formulation in cul-de-sac, 
enhanced corneal permeability across the corneal and conjunctival epithelium, 
enhanced ocular bioavailability, dual drug release profile in the eye and increased 
tolerability. Specifically, the dual drug release profile of nanocrystals in the eye 
means that they exhibit both immediate and sustained drug release profiles after 
their topical administration. The immediate drug release can be linked to the 
increased saturation solubility and dissolution of the nanocrystals resulting in 
initial higher concentrations available for absorption and thus rapid onset of action. 
The prolonged drug release, on the other hand, derives from the high surface area 
of the nanocrystals which facilitates interactions with biological membranes. The 
increased interactions with the ocular mucosa provide nanocrystals with 
mucoadhesive properties, increasing their retention time in the cul-de-sac region 
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and thus prolonged drug action is achieved. Increasing the viscosity of 
nanosuspensions or inclusion of nanocrystals into an in-situ gelling system can 
further increase the retention time and thus prolong the release profile of the drug 
[85].  
 
Tuomela et al. [58] prepared nanosuspensions of the poorly water-soluble drug 
brinzolamide as ocular formulations for the treatment of glaucoma. From the 
polymers/surfactants that were screened as stabilizers during wet media milling, 
hydroxypropyl methylcellulose was found to be the stabilizer of choice as it was 
capable of maintaining the reduced particle size of the nanosuspensions (~ 460 
nm). Both the cell viability results and the intraocular pressure effect achieved with 
the nanosuspensions were comparable with the marketed formulation of the drug 





8.5. Dermal drug delivery 
Dermal delivery of nanocrystals was a route of administration that was not fully 
exploited until lately, despite the advantages of nanocrystals such as adhesion, fast 
dissolution and increased penetration that can be of great importance for dermal 
application. The development of nanocrystals for delivery to the skin was firstly 
exploited in the field of cosmetics and it was later expanded for drug delivery 
purposes [23]. Specifically, the cosmetic products Juvedical ® (Juvena of 
Switzerland, Juvena Marlies Möller AG) and Platinum Rare collection (La Prairie 
®) contain nanocrystals of the antioxidants rutin and hesperidin, respectively. 
Incorporation of nanocrystals into these cosmetic products is straightforward as 
the aqueous nanosuspension is mixed with the cosmetic product (e.g. cream, 
lotion).  
 
Currently, apart from a wide range of antioxidants, drugs such as caffeine and 
diclofenac acid have been formulated as nanosuspensions for dermal application 
[86,87]. According to Vidlárova et al. [88], optimal dermal nanocrystal 
formulations should combine the following features: increased concentration 
gradient due to higher kinetic saturation solubility, low density of nanocrystals on 
the skin surface to cover densely enough the skin and sufficiently large area of 
direct contact of crystal surface to lipid films of the stratum corneum.  
 
Lai et al. [89] prepared nanosuspensions and nanoemulsions (oil-in-water) of 
tretinoin, an active compound widely used for the treatment of acne vulgaris. 
Dermal and transdermal delivery of both tretinoin nanoformulations were tested 
in vitro using Franz cells and newborn pig skin. Formulating tretinoin as a 
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nanosupension was found to favour drug accumulation into the skin (dermal 
delivery) and to minimize diffusion of the drug through the skin into the systemic 
circulation (transdermal delivery). On the contrary, a nanoemulsion is useful to 
improve both dermal and transdermal delivery. Moreover, photodegradation 
studies, using UV irradiation of the formulations, revealed that the nanosuspension 
could improve tretinoin's photostability compared to the nanoemulsion and the 
methanolic solution of the drug. Therefore, formulating tretinoin as 
nanosuspension appears to be a useful formulation approach for improving both 




9. Concluding remarks 
The number of drug candidates suffering from poor aqueous solubility is on the 
rise making poor solubility a major challenge for the pharmaceutical industry. 
Nanocrystals are nanosized drug particles produced as nanosuspensions in the 
presence of a stabilizer in order to achieve colloidal stability. Nanocrystals 
combine the advantages of increased saturation solubility and faster dissolution 
rate leading to enhanced bioavailability and reduced food effect for many drugs. 
Chemical stability and low toxicity of nanocrystals due to their high drug loading 
are also beneficial aspects of this formulation approach.  
 
Various methods have been investigated and patented for the preparation of 
nanosuspensions that can be classified as top-down (e.g. wet milling, high pressure 
homogenisation) and bottom-up techniques (e.g. antisolvent precipitation). 
Milling has a long history as a unit operation in pharmaceutical technology, but it 
is the advent of new devices with increased rotational speed and finer milling 
media that allows the use of milling as a nanonization technique. Currently, wet 
milling is the method behind most of the marketed nanocrystalline-based products. 
Planetary ball mills and wet stirred media mills are the main types of equipment 
that have been used to produce nanosuspensions, the first mainly for laboratory-
scale production and the latter for scaling-up purposes. The variety of poorly 
water-soluble drugs that have been processed to nanosuspensions using wet 
milling indicates the universality and versatility of this nanonization technique. 
Careful selection and optimisation of process and formulation parameters can 




Nanocrystalline-based formulations either as liquid nanosuspensions or after 
downstream processing to solid dosage forms have been mainly developed as oral 
and parenteral drug delivery systems. However, nanocrystalline-based 
formulations have been found to exhibit unique advantages for targeted delivery 
to the lungs, the eye and the skin. In conclusion, the number of nanocrystalline-
based products already commercially available together with the increasing 
number of scientific research and patents on drug nanocrystals for various 
applications indicate that both pharmaceutical industry and academia have 
embraced this universal formulation approach, which is expected to advance even 
more in the near future.  
 
Conflicts of interest 







[1] Bergström CAS, Charman WN, Porter CJH. Computational prediction of formulation 
strategies for beyond-rule-of-5 compounds. Adv Drug Deliv Rev 2016;101:6–21. 
doi:10.1016/j.addr.2016.02.005. 
[2] Lipinski C. Poor aqueous solubility - An industry wide problem in drug discovery. Am 
Pharm Rev 2002;5:82–5. 
[3] Gao L, Liu G, Ma J, Wang X, Zhou L, Li X, et al. Application of drug nanocrystal 
technologies on oral drug delivery of poorly soluble drugs. Pharm Res 2013;30:307–24. 
doi:10.1007/s11095-012-0889-z. 
[4] Brough C, Williams RO. Amorphous solid dispersions and nano-crystal technologies for 
poorly water-soluble drug delivery. Int J Pharm 2013;453:157–66. 
doi:10.1016/j.ijpharm.2013.05.061. 
[5] Perrie Y, Rades T. FASTtrack Pharmaceutics: Drug Delivery and Targeting. 2nd ed. 
London: Pharmaceutical Press; 2012.  
[6] Taniguchi N. On the basic concept of nanotechnology. Proc Intl Conf Prod Eng Tokyo, 
Part II, Japan Soc Precis Eng 1974:18–23. doi:10.1063/1.2836271. 
[7] Donaldson K, Poland CA. Nanotoxicity: Challenging the myth of nano-specific toxicity. 
Curr Opin Biotechnol 2013;24:724–34. doi:10.1016/j.copbio.2013.05.003. 
[8] Boverhof DR, Bramante CM, Butala JH, Clancy SF, Lafranconi M, West J, et al. 
Comparative assessment of nanomaterial definitions and safety evaluation considerations. 
Regul Toxicol Pharmacol 2015;73:137–50. 
doi:https://doi.org/10.1016/j.yrtph.2015.06.001. 
[9] Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high 
pressure homogenisation. Eur J Pharm Biopharm 2006;62:3–16. 
doi:10.1016/j.ejpb.2005.05.009. 
[10] Junghanns JUAH, Müller RH. Nanocrystal technology, drug delivery and clinical 
applications. Int J Nanomedicine 2008;3:295–309. doi:10.2147/IJN.S595. 
[11] Hafner A, Lovrić J, Lakoš GP, Pepić I. Nanotherapeutics in the EU: an overview on current 
state and future directions. Int J Nanomedicine 2014;9:1005–23. doi:10.2147/IJN.S55359. 
[12] Chingunpituk J. Nanosuspension Technology for Drug Delivery. Walailak J Sci Tech 
2007;4:139–53. 
[13] Wong J, Brugger A, Khare A, Chaubal M, Papadopoulos P, Rabinow B, et al. Suspensions 
for intravenous (IV) injection: A review of development, preclinical and clinical aspects. 
Adv Drug Deliv Rev 2008;60:939–54. doi:10.1016/j.addr.2007.11.008. 
[14] Yue PF, Li Y, Wan J, Yang M, Zhu WF, Wang CH. Study on formability of solid 
nanosuspensions during nanodispersion and solidification: I. Novel role of stabilizer/drug 
property. Int J Pharm 2013;454:269–77. doi:10.1016/j.ijpharm.2013.06.050. 
[15] Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: A 
perspective on formulating poorly-water soluble compounds using wet media milling 
technology. Adv Drug Deliv Rev 2011;63:427–40. doi:10.1016/j.addr.2010.12.007. 
[16] Verma S, Burgess D. Solid Nanosuspensions: The Emerging Technology and 
Pharmaceutical Applications as Nanomedicine. In: Kulshreshtha AK, Singh ON, Wall GM, 
editors. Pharmaceutical Suspensions From Formulation Development to Manufacturing, 
New York, NY: Springer New York; 2010, p. 285–318. doi:10.1007/978-1-4419-1087-
5_10. 
[17] Bitterlich A, Laabs C, Krautstrunk I, Dengler M, Juhnke M, Grandeury A, et al. Process 
parameter dependent growth phenomena of naproxen nanosuspension manufactured by 
wet media milling. Eur J Pharm Biopharm 2015;92:171–9. 
doi:10.1016/j.ejpb.2015.02.031. 
[18] Hasegawa Y, Higashi K, Yamamoto K, Moribe K. Direct evaluation of molecular states of 
37 
 
piroxicam/poloxamer nanosuspension by suspended-state NMR and Raman 
spectroscopies. Mol Pharm 2015;12:1564–72. doi:10.1021/mp500872g. 
[19] Lindfors L, Skantze P, Skantze U, Westergren J, Olsson U. Amorphous drug 
nanosuspensions. 3. Particle dissolution and crystal growth. Langmuir 2007;23:9866–74. 
doi:10.1021/la700811b. 
[20] Jog R, Burgess DJ. Pharmaceutical Amorphous Nanoparticles. J Pharm Sci 2017;106:39–
65. doi:10.1016/j.xphs.2016.09.014. 
[21] Romero GB, Arntjen A, Keck CM, Müller RH. Amorphous cyclosporin A nanoparticles 
for enhanced dermal bioavailability. Int J Pharm 2016;498:217–24. 
doi:10.1016/j.ijpharm.2015.12.019. 
[22] Tran TT-D, Tran PH-L, Nguyen MNU, Tran KTM, Pham MN, Tran PC, et al. Amorphous 
isradipine nanosuspension by the sonoprecipitation method. Int J Pharm 2014;474:146–50. 
doi:https://doi.org/10.1016/j.ijpharm.2014.08.017. 
[23] Shegokar R, Müller RH. Nanocrystals: Industrially feasible multifunctional formulation 
technology for poorly soluble actives. Int J Pharm 2010;399:129–39. 
doi:10.1016/j.ijpharm.2010.07.044. 
[24] Butler JM, Dressman JB. The developability classification system: Application of 
biopharmaceutics concepts to formulation development. J Pharm Sci 2010;99:4940–54. 
doi:10.1002/jps.22217. 
[25] Möschwitzer JP. Drug nanocrystals in the commercial pharmaceutical development 
process. Int J Pharm 2013;453:142–56. doi:10.1016/j.ijpharm.2012.09.034. 
[26] Shah DA, Murdande SB, Dave RH. A Review: Pharmaceutical and Pharmacokinetic 
Aspect of Nanocrystalline Suspensions. J Pharm Sci 2016;105:10–24. 
doi:10.1002/jps.24694. 
[27] Chen M-L, John M, Lee SL, Tyner KM. Development Considerations for Nanocrystal 
Drug Products. AAPS J 2017;19:642–51. doi:10.1208/s12248-017-0064-x. 
[28] Jain N, Yalkowsky SH. Estimation of the aqueous solubility I: Application to organic 
nonelectrolytes. J Pharm Sci 2001;90:234–52. doi:10.1002/1520-
6017(200102)90:2<234::AID-JPS14>3.0.CO;2-V. 
[29] Bergström CAS, Wassvik CM, Johansson K, Hubatsch I. Poorly soluble marketed drugs 
display solvation limited solubility. J Med Chem 2007;50:5858–62. 
doi:10.1021/jm0706416. 
[30] Tuomela A, Hirvonen J, Peltonen L. Stabilizing agents for drug nanocrystals: Effect on 
bioavailability. Pharmaceutics 2016;8. doi:10.3390/pharmaceutics8020016. 
[31] Buckton G, Beezer AE. The relationship between particle size and solubility. Int J Pharm 
1992;82:R7–10. doi:10.1016/0378-5173(92)90184-4. 
[32] Kesisoglou F, Panmai S, Wu Y. Nanosizing - Oral formulation development and 
biopharmaceutical evaluation. Adv Drug Deliv Rev 2007;59:631–44. 
doi:10.1016/j.addr.2007.05.003. 
[33] Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K, et al. The role of biopharmaceutics 
in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model 
predicts improved bioavailability and diminished food effect on absorption in human. Int 
J Pharm 2004;285:135–46. doi:10.1016/j.ijpharm.2004.08.001. 
[34] Van Eerdenbrugh B, Vermant J, Martens JA, Froyen L, Humbeeck J Van, Van Den Mooter 
G, et al. Solubility increases associated with crystalline drug nanoparticles: Methodologies 
and significance. Mol Pharm 2010;7:1858–70. doi:10.1021/mp100209b. 
[35] Jacobs C, Kayser O, Müller RH. Production and characterisation of mucoadhesive 
nanosuspensions for the formulation of bupravaquone. Int. J. Pharm., vol. 214, 2001, p. 3–
7. doi:10.1016/S0378-5173(00)00622-0. 
[36] Jain V, Kare P, Jain D, Singh R. Development and characterization of mucoadhesive 
nanosuspension of ciprofloxacin. Acta Pol Pharm - Drug Res 2011;68:273–8. 
[37] Gao L, Liu G, Wang X, Liu F, Xu Y, Ma J. Preparation of a chemically stable quercetin 
38 
 
formulation using nanosuspension technology. Int J Pharm 2011;404:231–7. 
doi:10.1016/j.ijpharm.2010.11.009. 
[38] Niwa T, Miura S, Danjo K. Universal wet-milling technique to prepare oral 
nanosuspension focused on discovery and preclinical animal studies - Development of 
particle design method. Int J Pharm 2011;405:218–27. doi:10.1016/j.ijpharm.2010.12.013. 
[39] Van Eerdenbrugh B, Van den Mooter G, Augustijns P. Top-down production of drug 
nanocrystals: Nanosuspension stabilization, miniaturization and transformation into solid 
products. Int J Pharm 2008;364:64–75. doi:10.1016/j.ijpharm.2008.07.023. 
[40] Verwey EJW. Theory of the stability of lyophobic colloids. J Phys Colloid Chem 
1947;51:631–6. doi:10.1038/162315b0. 
[41] Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv 
Drug Deliv Rev 2011;63:456–69. doi:10.1016/j.addr.2011.02.001. 
[42] Zhu Z, Margulis-Goshen K, Magdassi S, Talmon Y, Macosko CW. Polyelectrolyte 
stabilized drug nanoparticles via flash nanoprecipitation: A model study with ??-carotene. 
J Pharm Sci 2010;99:4295–306. doi:10.1002/jps.22090. 
[43] Bilgili E, Li M, Afolabi A. Is the combination of cellulosic polymers and anionic 
surfactants a good strategy for ensuring physical stability of BCS Class II drug 
nanosuspensions? Pharm Dev Technol 2015;0:1–12. 
doi:10.3109/10837450.2015.1022788. 
[44] Peltonen L, Tuomela A, Hirvonen J. Polymeric Stabilizers for Drug Nanocrystals. In 
Thakur VK, Thakur ML, editors. Handbook of Polymers for Pharmaceutical Technologies, 
Volume 4, John Wiley & Sons, Inc.; 2015, p. 67–87. doi:10.1002/9781119041559.ch3. 
[45] Malamatari M, Somavarapu S, Bloxham M, Buckton G. Nanoparticle agglomerates of 
indomethacin: The role of poloxamers and matrix former on their dissolution and 
aerosolisation efficiency. Int J Pharm 2015;495:516–26. 
[46] Ito A, Konnerth C, Schmidt J, Peukert W. Effect of polymer species and concentration on 
the production of mefenamic acid nanoparticles by media milling. Eur J Pharm Biopharm 
2016;98:98–107. doi:10.1016/j.ejpb.2015.11.011. 
[47] Verma S, Kumar S, Gokhale R, Burgess DJ. Physical stability of nanosuspensions: 
Investigation of the role of stabilizers on Ostwald ripening. Int J Pharm 2011;406:145–52. 
doi:10.1016/j.ijpharm.2010.12.027. 
[48] George M, Ghosh I. Identifying the correlation between drug/stabilizer properties and 
critical quality attributes (CQAs) of nanosuspension formulation prepared by wet media 
milling technology. Eur J Pharm Sci 2013;48:142–52. doi:10.1016/j.ejps.2012.10.004. 
[49] Van Eerdenbrugh B, Vermant J, Martens JA, Froyen L, Van Humbeeck J, Augustijns P, et 
al. A screening study of surface stabilization during the production of drug nanocrystals. J 
Pharm Sci 2009;98:2091–103. doi:10.1002/jps.21563. 
[50] Lestari MLAD, Müller RH, Möschwitzer JP. Systematic screening of different surface 
modifiers for the production of physically stable nanosuspensions. J Pharm Sci 
2015;104:1128–40. doi:10.1002/jps.24266. 
[51] Zhang J, Wu L, Chan HK, Watanabe W. Formation, characterization, and fate of inhaled 
drug nanoparticles. Adv Drug Deliv Rev 2011;63:441–55. 
doi:10.1016/j.addr.2010.11.002. 
[52] Heinicke. Tribochemistry. Academie-Verlag, Berlin; 1984. 
[53] Stenger F, Peukert W. The role of particle interactions on suspension rheology - 
Application to submicron grinding in stirred ball mills. Chem Eng Technol 2003;26:177–
83. doi:10.1002/ceat.200390026. 
[54] Bilgili E, Capece M, Afolabi A. Modeling of milling processes via DEM, PBM, and 
microhydrodynamics. Predict. Model. Pharm. Unit Oper., 2016, p. 159–203. 
doi:10.1016/B978-0-08-100154-7.00007-7. 
[55] Atiemo-Obeng VA, Calabrese R V. Rotor–Stator Mixing Devices. Handb. Ind. Mix., John 
Wiley & Sons, Inc.; 2004, p. 479–505. doi:10.1002/0471451452.ch8. 
39 
 
[56] Broseghini M, D’Incau M, Gelisio L, Pugno NM, Scardi P. Effect of jar shape on high-
energy planetary ball milling efficiency: Simulations and experiments. Mater Des 
2016;110:365–74. doi:10.1016/j.matdes.2016.06.118. 
[57] Steiner D, Finke JH, Breitung-Faes S, Kwade A. Breakage, temperature dependency and 
contamination of Lactose during ball milling in ethanol. Adv Powder Technol 
2016;27:1700–9. doi:10.1016/j.apt.2016.05.034. 
[58] Tuomela A, Liu P, Puranen J, Rönkkö S, Laaksonen T, Kalesnykas G, et al. Brinzolamide 
nanocrystal formulations for ophthalmic delivery: Reduction of elevated intraocular 
pressure in vivo. Int J Pharm 2014;467:34–41. doi:10.1016/j.ijpharm.2014.03.048. 
[59] Juhnke M, Berghausen J, Timpe C. Accelerated formulation development for nanomilled 
active pharmaceutical ingredients using a screening approach. Chem Eng Technol 
2010;33:1412–8. doi:10.1002/ceat.201000062. 
[60] Kwade A. Wet comminution in stirred media mills - Research and its practical application. 
Powder Technol., vol. 105, 1999, p. 14–20. doi:10.1016/S0032-5910(99)00113-8. 
[61] Afolabi A, Akinlabi O, Bilgili E. Impact of process parameters on the breakage kinetics of 
poorly water-soluble drugs during wet stirred media milling: A microhydrodynamic view. 
Eur J Pharm Sci 2014;51:75–86. doi:10.1016/j.ejps.2013.09.002. 
[62] Li M, Alvarez P, Bilgili E. A microhydrodynamic rationale for selection of bead size in 
preparation of drug nanosuspensions via wet stirred media milling. Int J Pharm 
2017;524:178–92. doi:10.1016/j.ijpharm.2017.04.001. 
[63] Monteiro A, Afolabi A, Bilgili E. Continuous production of drug nanoparticle suspensions 
via wet stirred media milling: a fresh look at the Rehbinder effect. Drug Dev Ind Pharm 
2012;39:1–18. doi:10.3109/03639045.2012.676048. 
[64] Malamatari M, Somavarapu S, Taylor KMG, Buckton G. Solidification of 
nanosuspensions for the production of solid oral dosage forms and inhalable dry powders. 
Expert Opin Drug Deliv 2016;13:435–50. 
[65] Chaubal M V., Popescu C. Conversion of nanosuspensions into dry powders by spray 
drying: A case study. Pharm Res 2008;25:2302–8. doi:10.1007/s11095-008-9625-0. 
[66] Vasquez EM. Sirolimus: A new agent for prevention of renal allograft rejection. Am J Heal 
Pharm 2000;57:437–51. 
[67] Merisko-Liversidge E. Nanosizing: ``End-to-End’’ Formulation Strategy for Poorly 
Water-Soluble Molecules. In: Templeton AC, Byrn SR, Haskell RJ, Prisinzano TE, editors. 
Discovery and Developing Molecules with Optimal Drug-Like Properties, New York, NY: 
Springer New York; 2015, p. 437–67. doi:10.1007/978-1-4939-1399-2_13. 
[68] Downing NS, Ross JS, Jackevicius CA, Krumholz HM. Avoidance of Generic Competition 
by Abbott Laboratories’ Fenofibrate Franchise. Arch Intern Med 2012;172:724–30. 
doi:10.1001/archinternmed.2012.187. 
[69] Müller RH, Gohla S, Keck CM. State of the art of nanocrystals – Special features, 
production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm 
2011;78:1–9. doi:https://doi.org/10.1016/j.ejpb.2011.01.007. 
[70] Pawar VK, Singh Y, Meher JG, Gupta S, Chourasia MK. Engineered nanocrystal 
technology: In-vivo fate, targeting and applications in drug delivery. J Control Release 
2014;183:51–66. doi:10.1016/j.jconrel.2014.03.030. 
[71] Gao L, Liu G, Ma J, Wang X, Zhou L, Li X. Drug nanocrystals: In vivo performances. J 
Control Release 2012;160:418–30. doi:10.1016/j.jconrel.2012.03.013. 
[72] Sun B, Yeo Y. Nanocrystals for the parenteral delivery of poorly water-soluble drugs. Curr 
Opin Solid State Mater Sci 2012;16:295–301. doi:10.1016/j.cossms.2012.10.004. 
[73] Shegokar R, Singh KK. Surface modified nevirapine nanosuspensions for viral reservoir 
targeting: In vitro and in vivo evaluation. Int J Pharm 2011;421:341–52. 
doi:10.1016/j.ijpharm.2011.09.041. 
[74] Tolman JA, Williams RO. Advances in the pulmonary delivery of poorly water-soluble 




[75] Yang W, Tam J, Miller DA, Zhou J, McConville JT, Johnston KP, et al. High 
bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible 
stabilizers. Int J Pharm 2008;361:177–88. doi:10.1016/j.ijpharm.2008.05.003. 
[76] Britland S, Finter W, Chrystyn H, Eagland D, Abdelrahim ME. Droplet aerodynamics, 
cellular uptake, and efficacy of a nebulizable corticosteroid nanosuspension are superior to 
a micronized dosage form. Biotechnol Prog 2012;28:1152–9. doi:10.1002/btpr.1616. 
[77] Yamasaki K, Kwok PCL, Fukushige K, Prud’Homme RK, Chan HK. Enhanced dissolution 
of inhalable cyclosporine nano-matrix particles with mannitol as matrix former. Int J Pharm 
2011;420:34–42. doi:10.1016/j.ijpharm.2011.08.010. 
[78] Malamatari M, Somavarapu S, Kachrimanis K, Bloxham M, Taylor KMG, Buckton G. 
Preparation of theophylline inhalable microcomposite particles by wet milling and spray 
drying: The influence of mannitol as a co-milling agent. Int J Pharm 2016;514. 
doi:10.1016/j.ijpharm.2016.06.032. 
[79] El-Gendy N, Desai V, Berkland C. Agglomerates of ciprofloxacin nanoparticles yield fine 
dry powder aerosols. J Pharm Innov 2010;5:79–87. doi:10.1007/s12247-010-9082-2. 
[80] El-Gendy N, Pornputtapitak W, Berkland C. Nanoparticle agglomerates of fluticasone 
propionate in combination with albuterol sulfate as dry powder aerosols. Eur J Pharm Sci 
2011;44:522–33. doi:10.1016/j.ejps.2011.09.014. 
[81] Malamatari M, Somavarapu S, Bloxham M, Buckton G. Nanoparticle agglomerates of 
indomethacin: The role of poloxamers and matrix former on their dissolution and 
aerosolisation efficiency. Int J Pharm 2015;495:516–26. 
doi:10.1016/j.ijpharm.2015.09.013. 
[82] Malamatari M, Somavarapu S, Kachrimanis K, Buckton G, Taylor KMG. Preparation of 
respirable nanoparticle agglomerates of the low melting and ductile drug ibuprofen: Impact 
of formulation parameters. Powder Technol 2017;308. doi:10.1016/j.powtec.2016.12.007. 
[83] Reimondez-Troitiño S, Csaba N, Alonso MJ, de la Fuente M. Nanotherapies for the 
treatment of ocular diseases. Eur J Pharm Biopharm 2015;95:279–93. 
doi:10.1016/j.ejpb.2015.02.019. 
[84] Sharma OP, Patel V, Mehta T. Nanocrystal for ocular drug delivery: hope or hype. Drug 
Deliv Transl Res 2016;6:399–413. doi:10.1007/s13346-016-0292-0. 
[85] Gupta S, Samanta MK, Raichur AM. Dual-drug delivery system based on in situ gel-
forming nanosuspension of forskolin to enhance antiglaucoma efficacy. AAPS 
PharmSciTech 2010;11:322–35. doi:10.1208/s12249-010-9388-x. 
[86] Zhai X, Lademann J, Keck CM, Müller RH. Dermal nanocrystals from medium soluble 
actives - Physical stability and stability affecting parameters. Eur J Pharm Biopharm 
2014;88:85–91. doi:10.1016/j.ejpb.2014.07.002. 
[87] Pireddu R, Caddeo C, Valenti D, Marongiu F, Scano A, Ennas G, et al. Diclofenac acid 
nanocrystals as an effective strategy to reduce in vivo skin inflammation by improving 
dermal drug bioavailability. Colloids Surfaces B Biointerfaces 2016;143:64–70. 
doi:10.1016/j.colsurfb.2016.03.026. 
[88] Vidlářová L, Romero GB, Hanuš J, Štěpánek F, Müller RH. Nanocrystals for dermal 
penetration enhancement - Effect of concentration and underlying mechanisms using 
curcumin as model. Eur J Pharm Biopharm 2016;104:216–25. 
doi:10.1016/j.ejpb.2016.05.004. 
[89] Lai F, Pireddu R, Corrias F, Fadda AM, Valenti D, Pini E, et al. Nanosuspension improves 







Figure 1. A nanoscale comparison and types of nanotherapeutics used in drug 
delivery. 
Figure 2. Scanning electron microscopy images (top) of (a) the poorly water-
soluble antifungal drug, posaconazole starting material and (b) posaconazole 
nanocrystals produced by wet milling. The particle size distribution graphs 
(bottom) were determined using laser light diffraction after suitable dilution by 
distilled water. Reproduced with permission from [15]. 
Figure 3. A suitable concentration of stabilizer should be present in the system to 
produce nanosuspensions with small particle size and to assure colloidal stability. 
Excess stabilizer should be avoided to prevent solubilisation and increase of 
particle size due to Ostwald ripening. Adapted with permission from [46]. 
Figure 4. Schematic drawing of a planetary ball mill: (a) three-dimensional view, 
(b) top and (c) sectional view. Rj: the jar radius, Rp: the disk radius, ω: angular 
velocity of grinding jar around the planetary axis and Ω: angular velocity of 
rotating disk around the sun axis. Reproduced with permission from [56]. 
 
Figure 5. Schematic drawing of a wet stirred media mill (Microcer model, Netzsch 
Fine Particle Technology, USA) operating in the recirculation mode. P and T stand 
for pressure and temperature sensor, respectively. Reproduced with permission 
from [61].  
Figure 6. Preparation of respirable nanoparticle agglomerates by combining wet 
milling and spray drying. “Road map” developed to guide the selection of 
formulation and process parameters that should be adjusted to engineer inhalable 
nanoparticle agglomerates, by considering the physicochemical properties of the 
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